Press releases
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
More ▼
Key statistics
On Wednesday, Arrowhead Pharmaceuticals Inc (0HI3:LSE) closed at 23.12, 11.42% above the 52 week low of 20.75 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 23.12 |
Average volume | 1.03k |
---|---|
Shares outstanding | 123.90m |
Free float | 118.33m |
P/E (TTM) | -- |
Market cap | 2.95bn USD |
EPS (TTM) | -2.77 USD |
Data delayed at least 20 minutes, as of Apr 24 2024 18:34 BST.
More ▼